Clinical Scorecard: Comprehensive Transcriptomic and Single-Cell Analyses Enhanced by Artificial Neural Networks Reveal a Distinct Gene Signature for Early Differentiation of MASL and MASH

At a Glance

Key Highlights

• Identification of six key genes (MMP9, FABP5, TREM2, CTSD, UBD, MAP2K1) differentiating MASL from MASH with high diagnostic accuracy
• Artificial neural network model achieved an AUC of 0.893 in validation cohort for early discrimination between MASL and MASH
• Immune infiltration analysis revealed increased monocytes, M0/M1 macrophages, and activated dendritic cells in MASH, with key genes localized to myeloid populations

Guideline-Based Recommendations

Diagnosis

• Use molecular gene signatures derived from transcriptomic and single-cell analyses to improve early differentiation of MASL and MASH
• Consider artificial neural network-based classifiers incorporating key gene expression for noninvasive diagnostic support
• Recognize limitations of liver biopsy and imaging modalities in early-stage discrimination

Management

• Lifestyle modification remains cornerstone of MASLD management
• Monitor patients with MASL for progression to MASH using emerging molecular diagnostic tools
• Address metabolic risk factors such as obesity and type 2 diabetes to reduce disease progression

Monitoring & Follow-up

• Employ gene signature-based assays to monitor disease progression and subtype differentiation
• Assess immune cell infiltration patterns as potential markers of disease activity
• Use quantitative PCR validation in clinical samples to confirm molecular findings

Risks

• Invasive liver biopsy carries risks including bleeding and infection
• Current serum biomarkers and imaging techniques have limited specificity and accessibility
• Delayed diagnosis of MASH can lead to fibrosis, cirrhosis, and hepatocellular carcinoma

Patient & Prescribing Data

Patients with metabolic dysfunction-associated steatotic liver disease, including those with obesity and type 2 diabetes

No effective pharmacological therapies currently established; emphasis on early detection to guide lifestyle interventions and prevent progression

Clinical Best Practices

• Integrate multi-cohort transcriptomic data and machine learning algorithms for robust diagnostic gene signature development
• Utilize artificial neural networks to enhance diagnostic accuracy for MASL versus MASH differentiation
• Incorporate immune cell composition analysis to understand disease mechanisms and guide personalized care
• Validate molecular findings with quantitative PCR in clinical liver tissue samples
• Prioritize noninvasive diagnostic approaches to improve patient acceptance and reduce procedural risks

References

• Global prevalence and burden of MASLD
• Multiple hit hypothesis in MASLD progression
• Machine learning-derived gene signature for MASH diagnosis
• Limitations of liver biopsy and imaging in MASLD